Fly News Breaks for April 12, 2019
PDLI, EVFM
Apr 12, 2019 | 06:55 EDT
Oppenheimer analyst Leland Gershell raised his price target for Evofem Biosciences (EVFM) to $11 from $9 following yesterday's announcement of the securities purchase agreement with PDL BioPharma (PDLI), which he says cures a significant financing overhang on favorable terms, mitigates uncertainty around U.S. commercial economics, and provides validation by a well-regarded strategic healthcare investor. He maintains an Outperform rating.
News For EVFM;PDLI From the Last 2 Days
There are no results for your query EVFM;PDLI